Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FGEN
stocks logo

FGEN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.67M
-96.69%
-3.885
+94.25%
0.00
-100%
-4.290
-443.2%
0.00
-100%
-4.250
+126.06%
Estimates Revision
The market is revising No Change the revenue expectations for FibroGen, Inc. (FGEN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -31.82%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-31.82%
In Past 3 Month
Wall Street analysts forecast FGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FGEN is 43.00 USD with a low forecast of 43.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FGEN is 43.00 USD with a low forecast of 43.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 8.250
sliders
Low
43.00
Averages
43.00
High
43.00
Current: 8.250
sliders
Low
43.00
Averages
43.00
High
43.00
H.C. Wainwright
H.C. Wainwright
NULL -> Buy
upgrade
$10 -> $43
2025-08-07
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10 -> $43
2025-08-07
upgrade
NULL -> Buy
Reason
H.C. Wainwright adjusted the firm's price target on FibroGen to $43 from $10 and keeps a Buy rating on the shares following the recent reverse stock split. The firm also cites an increased discount rate pending visibility from both the FG-3246 and roxadustat programs after Fibrogen disclosed "positive details" from a Type C meeting with the FDA. The firm, which calls the update an "important step forward for Fibrogen and roxa," awaits additional updates, including trial start dates and possible inclusion of a development/commercial partner.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$10
2025-03-18
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$10
2025-03-18
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$10
2025-02-20
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$10
2025-02-20
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for FibroGen Inc (FGEN.O) is -0.49, compared to its 5-year average forward P/E of -5.49. For a more detailed relative valuation and DCF analysis to assess FibroGen Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.49
Current PE
-0.49
Overvalued PE
2.64
Undervalued PE
-13.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.11
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
7.03
Undervalued EV/EBITDA
-17.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.45
Current PS
0.00
Overvalued PS
10.09
Undervalued PS
0.82
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

FGEN News & Events

Events Timeline

(ET)
2025-11-10
16:14:27
FibroGen Announces Q3 Earnings Per Share of $3.25, Below Consensus Estimate of $4.01
select
2025-09-24 (ET)
2025-09-24
07:03:24
FibroGen Launches Phase 2 Study of FG-3246
select
2025-09-10 (ET)
2025-09-10
15:49:42
SEC Accuses Former FibroGen CMO of Misleading Statements Regarding Clinical Trial Outcomes
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-03Globenewswire
FibroGen to Present at Oppenheimer Rare Disease Summit with Key Catalysts
  • Key Conference Participation: FibroGen will attend the Oppenheimer Rare Disease Summit on December 11, 2025, in New York, where CEO Thane Wettig will participate in a panel discussing potential stock-moving catalysts in rare diseases, highlighting the company's strategic focus.
  • One-on-One Investor Meetings: The management team will be available for one-on-one meetings during the conference, aiming to attract investor interest in their novel therapies, particularly Roxadustat for chronic kidney disease patients and FG-3246 for prostate cancer treatment.
  • New Therapy Development: FibroGen is evaluating the Phase 3 trial plan for Roxadustat in the U.S. targeting lower-risk myelodysplastic syndrome (LR-MDS), which, if successful, could present significant market opportunities for the company.
  • Frontier Biopharmaceuticals: As a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia, FibroGen's innovative drugs like FG-3246 and FG-3180 have the potential to transform treatment paradigms, enhancing the company's competitiveness in the biopharmaceutical sector.
[object Object]
Preview
1.0
12-03Newsfilter
FibroGen to Present at Oppenheimer Rare Disease Summit on December 11
  • Executive Participation: FibroGen's CEO Thane Wettig will participate in a panel at the Rare Disease Summit on December 11 in New York, showcasing the company's potential catalysts in the rare disease space, aimed at attracting investor attention and enhancing market awareness.
  • One-on-One Meetings: The management team will offer one-on-one investor meetings during the conference, designed to strengthen connections with potential investors and drive positive stock performance through direct engagement.
  • Product Development Progress: FibroGen's Roxadustat is approved in Europe and Japan for treating anemia in chronic kidney disease patients, demonstrating the company's innovative capabilities and market potential in the biopharmaceutical sector.
  • Clinical Trial Plans: The company is evaluating the Phase 3 trial plan for Roxadustat in the U.S. for lower-risk myelodysplastic syndrome, which, if successful, will further solidify its leadership position in the anemia treatment market.
[object Object]
Preview
8.5
08-18Newsfilter
FibroGen Receives Approval from China's Market Regulation Authority for Sale of FibroGen China to AstraZeneca

  • Sale Approval: The China State Administration for Market Regulation has approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, as per a Share Purchase Agreement dated February 20, 2025.

  • Closing Timeline: The transaction is expected to close in the third quarter of 2025, pending other contractual closing conditions and deliverables.

  • Company Overview: FibroGen, Inc. focuses on developing novel therapies for cancer biology and anemia, with its product Roxadustat already approved in multiple countries for treating anemia in chronic kidney disease patients.

  • Forward-Looking Statements: The release includes forward-looking statements regarding FibroGen's future plans and clinical programs, cautioning investors about potential risks and uncertainties that may affect actual results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is FibroGen Inc (FGEN) stock price today?

The current price of FGEN is 8.25 USD — it has increased 1.6 % in the last trading day.

arrow icon

What is FibroGen Inc (FGEN)'s business?

FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).

arrow icon

What is the price predicton of FGEN Stock?

Wall Street analysts forecast FGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FGEN is 43.00 USD with a low forecast of 43.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is FibroGen Inc (FGEN)'s revenue for the last quarter?

FibroGen Inc revenue for the last quarter amounts to 1.08M USD, increased 774.80 % YoY.

arrow icon

What is FibroGen Inc (FGEN)'s earnings per share (EPS) for the last quarter?

FibroGen Inc. EPS for the last quarter amounts to 49.61 USD, decreased -1267.29 % YoY.

arrow icon

What changes have occurred in the market's expectations for FibroGen Inc (FGEN)'s fundamentals?

The market is revising No Change the revenue expectations for FibroGen, Inc. (FGEN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -31.82%.
arrow icon

How many employees does FibroGen Inc (FGEN). have?

FibroGen Inc (FGEN) has 225 emplpoyees as of December 05 2025.

arrow icon

What is FibroGen Inc (FGEN) market cap?

Today FGEN has the market capitalization of 33.37M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free